Literature DB >> 21687953

Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells.

Yoriko Yoshizawa1, Yoshihiko Yamada, Seiji Kanayama, Hiroshi Shigetomi, Ryuji Kawaguchi, Shozo Yoshida, Akira Nagai, Naoto Furukawa, Hidekazu Oi, Hiroshi Kobayashi.   

Abstract

Hepatocyte growth factor (HGF) is up-regulated in tissue repair and has been implicated in playing a role in this process through its anti-apoptotic and proliferative activities. Cyclooxygenase-2 (COX-2) is an inducible enzyme in the biosynthetic pathway of prostaglandins, and its activation has been shown to play an important role in cell growth. We previously reported that HGF significantly inhibited anoikis, possibly through the up-regulation of COX-2 expression in the endometrial RL95-2 cancer cell line. Here, we report that i) treatment of RL95-2 cells with HGF resulted in phosphorylation of the HGF receptor c-Met, activation of Akt and IκB, translocation of NF-κB into the nucleus, and up-regulation of COX-2 mRNA; ii) the IκB-α phosphorylation inhibitor BAY11-7082 and the selective COX-2 inhibitor CAY10452 blocked HGF-mediated anoikis resistance in RL95-2 cells; and iii) HGF induced migration and invasion in RL95-2 cells, while the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and CAY10452 blocked these effects of HGF stimulation. Our data suggest that HGF possesses chemotactic ability, has anti-apoptosis action, and induces cellular infiltration via the PI3K/Akt pathway; it also triggers NF-κB activation and up-regulates COX-2 gene expression in endometrial cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21687953     DOI: 10.3892/or.2011.1348

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin.

Authors:  Jing Liu; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

2.  Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.

Authors:  Gaurav Kumar; S Nahum Goldberg; Yuanguo Wang; Erik Velez; Svetlana Gourevitch; Eithan Galun; Muneeb Ahmed
Journal:  Eur Radiol       Date:  2016-06-10       Impact factor: 5.315

3.  Measurement of Serum and Hepatic Eicosanoids by Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS) in a Mouse Model of Hepatocellular Carcinoma (HCC) with Delivery of c-Met and Activated β-Catenin by Hepatocyte Hydrodynamic Injection.

Authors:  Yanjie Li; Nan Lin; Jianliang Xu; Yi Lu; Shuxian Chen; Chuzhi Pan; Chusi Wang; Mingxing Xu; Boxuan Zhou; Ruiyun Xu; Yong-Jiang Xu
Journal:  Med Sci Monit       Date:  2018-03-21

4.  A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Authors:  Douglas C Marchion; Elona Bicaku; Yin Xiong; Nadim Bou Zgheib; Entidhar Al Sawah; Xiaomang Ba Stickles; Patricia L Judson; Alex S Lopez; Christopher L Cubitt; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Anders Berglund; Johnathan M Lancaster
Journal:  Oncol Rep       Date:  2013-03-05       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.